News Search Results

Displaying Results 51-75 of 657 "ophthalmology"

Dec 03, 2025, 08:56 ET Dicom Systems Processes 124 Billion Medical Images Annually and Achieves ISO 27001 Certification, CE Mark, Expands Digital Pathology and Reseller Partnerships

Unifier platform reflects growing demand for scalable interoperability across radiology, cardiology, ophthalmology, and digital pathology. Deployed at over 630 sites globally, Unifier enables secure, efficient data exchange between imaging modalities, PACS, EHR

More news about: Dicom Systems


Dec 03, 2025, 08:00 ET Johnson & Johnson Teams Up with Naomi Watts to Reveal Why an Eye Exam is the Ultimate Self-Care Move for Women Over 40

a paid endorsement. Naomi Watts was compensated for this quote.1 How hormones can affect eyes and vision. American Academy of Ophthalmology. (2018, November 12).

More news about: Johnson & Johnson MedTech


Dec 03, 2025, 08:00 ET Stellaromics Establishes First U.S. Pyxa™ 3D Spatial Transcriptomics Site at UC Irvine

laboratory of Dr. Rui Chen, Professor of Ophthalmology at the Gavin Herbert Eye Institute, Robert M. Brunson Center for Translational Vision Research. Internationally recognized for his work mapping

More news about: Stellaromics


Dec 03, 2025, 05:00 ET Formosa Pharmaceuticals Announces Licensing Agreement with Rxilient, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery

Pharmaceuticals, Inc.Formosa Pharmaceuticals, Inc. (6838.TW) is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's proprietary nanoparticle formulation technology (APNT®), through which APP13007 was developed, improves the

More news about: Formosa Pharmaceuticals Inc.,


Dec 02, 2025, 19:43 ET Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®

monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific

More news about: Celltrion


Dec 02, 2025, 16:47 ET Avetra Launches as a Next-Generation, Site-Centric CRO Transforming Clinical Trial Operations

Network & Integrated Laboratory CapabilitiesAvetra's network spans leading research sites across gastroenterology, endocrinology, ophthalmology, obesity, vaccines, and additional therapeutic areas. Its central laboratory division will further streamline specimen handling, logistics, and

More news about: Avetra, Inc


Dec 02, 2025, 10:00 ET Avisi Technologies Announces First Patient Implanted with VisiPlate® Glaucoma Treatment Device in the SAPPHIRE Trial

options. VisiPlate® has been previously studied in the VITA Trial with long-term follow up data presented at the 2025 American Academy of Ophthalmology annual meeting."VisiPlate is an advanced technology designed to maximize patients' quality of life. Dr. Snyder's successful VisiPlate surgery

More news about: Avisi Technologies, Inc.


Dec 02, 2025, 06:42 ET Prefilled Syringes (PFS) Market Size to Grow USD 32.98 Billion by 2035 at a CAGR 13.75 | Vantage Market Research

low-molecular-weight heparin (LMWH) are major contributors, supported by high hospital usage and at-home post-surgical care management.Ophthalmology: Rising incidence of retinal disorders and growing use of intravitreal injections drive uptake of precision-engineered prefilled syringes designed

More news about: Vantage Market Research


Dec 02, 2025, 06:40 ET Prescription Drugs Market Poised for Substantial Growth, Driven by Novel Therapies and Evolving Regulatory Landscape: Reaching US$2.15 Trillion by 2032

market share, driven by a growing patient pool and the successful launch of biologic therapies. Other significant therapeutic areas, including Ophthalmology, Respiratory, Gastroenterology, and Gynecology, collectively account for the remainder, addressing a wide spectrum of patient

More news about: DataM Intelligence 4 Market Research LLP


Nov 28, 2025, 04:06 ET China's First Domestic IL-23p19 Monoclonal Antibody: Innovent's PECONDLE® (Picankibart Injection) Received NMPA Approval

aiming to address unmet clinical needs such as drug resistance and disease recurrence. Innovent will continue to expand its innovative portfolio in ophthalmology, autoimmune diseases, and cardiovascular and metabolic (CVM) conditions, with the aim to help more people achieve healthier lives."

More news about: Innovent Biologics


Nov 27, 2025, 00:14 ET B Prabhakaran visits Lloyds Kali Ammal Memorial (LKAM) Hospital to celebrate the milestone of 300th Baby Delivery

operates as a 30-bed multispecialty centre offering medical services across emergency care, obstetrics, paediatrics, general medicine, dentistry and ophthalmology, supported by modern diagnostics and a dedicated clinical team. The hospital serves between 100 and 150 patients each day and has become a trusted

More news about: Lloyds Kali Ammal Memorial (LKAM) Hospital


Nov 26, 2025, 14:19 ET Piramal Pharma Solutions Achieves Regulatory Compliance for Nitrosamine Impurities

associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics

More news about: Piramal Pharma Solutions


Nov 26, 2025, 14:13 ET Piramal Pharma Solutions Achieves Regulatory Compliance for Nitrosamine Impurities

associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics

More news about: Piramal Pharma Solutions


Nov 26, 2025, 08:00 ET SECTRA LAUNCHES ITS BUILT-IN REPORTING SOLUTION IN THE US--ACCELERATES DIAGNOSTICS FOR IMPROVED PATIENT CARE

Sectra offers a complete enterprise solution comprised of imaging modules (radiology, cardiology, pathology, orthopedics, genomics and ophthalmology), and a robust VNA. Over the last consecutive twelve years, Sectra has been awarded Best in KLAS for highest

More news about: Sectra


Nov 26, 2025, 01:48 ET Celltrion announces publication of post-hoc analysis of LIBERTY-CD study of ZYMFENTRA® (infliximab-dyyb), indicating consistent efficacy across disease location, including the terminal ileum in Clinical Gastroenterology and Hepatology journal

monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific

More news about: Celltrion


Nov 25, 2025, 22:51 ET FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamous cell carcinoma (aCSCC)

U.S. as well as global Emerging Markets. Sun Pharma's high-growth global Innovative Medicines portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for about 20% of company sales. The company's vertically integrated operations deliver high-quality medicines,

More news about: Sun Pharma


Nov 25, 2025, 14:01 ET From Tradition to Tomorrow: PIH Health Good Samaritan Hospital Celebrates 140 Years of Excellence

cardiothoracic surgery), women's health (obstetrics, gynecology, neonatal intensive care, and gynecologic oncology), breast care, orthopedic surgery, ophthalmology, oncology, digestive diseases, kidney stone treatment, and more.PIH Health Good Samaritan Hospital remains a pillar of the Los Angeles medical

More news about: PIH Health


Nov 25, 2025, 09:45 ET To Educate the Public and Raise Awareness, Prevent Blindness Declares Fifth Annual Geographic Atrophy Week as Dec. 1-7, 2025

Advancements in Treatments for Geographic Atrophy," featuring Rajeev S. Ramchandran, MD, MBA, Associate Professor of Ophthalmology, Flaum Eye Institute, University of Rochester Medical Center."

More news about: Prevent Blindness


Nov 25, 2025, 09:00 ET Neurophet and The Florey Strengthen Research Collaboration on 'Neurophet AQUA' to Advance Alzheimer's Disease Diagnosis

schizophrenia, and bipolar disorder.Professor Peter van Wijngaarden, Executive Director and CEO of the Florey and Honorary Professor of Ophthalmology at the University of Melbourne, has a strong research interest in biomarkers of neurodegenerative diseases. "We are delighted to announce this research

More news about: Neurophet


Nov 25, 2025, 04:35 ET TCL CSOT Unveils "2025 Eye-Care Technology White Paper", Setting New Benchmarks for Natural-Light Display Standards

advanced display technologies and a subsidiary of TCL Technology (000100.SZ), in collaboration with the National Engineering Research Center for Ophthalmology & Optometry of Wenzhou Medical University in China, and leading industry partners including Lenovo, CVTE, TAL Education, the China Institute

More news about: TCL China Star Optoelectronics Technology


Nov 24, 2025, 13:29 ET U.S. Software as a Medical Device Market to Reach USD 715 Million by 2033 as AI-Driven Diagnostics and Digital Therapeutics Accelerate Adoption

hospitalizations.DiagnosticsDiagnostics accounted for 29% of the market, valued at USD 59 million. AI-based imaging analytics, digital pathology platforms, ophthalmology screening tools, and virtual ECG diagnostic engines are gaining strong adoption among U.S. hospitals. FDA-cleared AI diagnostic tools, especially

More news about: DataM Intelligence 4 Market Research LLP


Nov 24, 2025, 06:03 ET Cell Therapy Market Size Set to More Than Double by 2030 -- North America Leads, While Asia-Pacific Emerges as the Fastest-Growing Region, Says Mordor Intelligence

DiseasesOrthopedic & MusculoskeletalNeurological DisordersAutoimmune DisordersWound Healing & DermatologyOphthalmologyBy End UserHospitals & ClinicsSpecialty Cell- & Gene-Therapy CentersAcademic

More news about: Mordor Intelligence Private Limited


Nov 24, 2025, 03:07 ET Sectra at RSNA 2025: Supporting subspecialty workflows and photon-counting CT at the workstation to reduce burnout risk and improve patient care

Sectra will showcase its complete enterprise imaging portfolio comprised of diagnostic modules (radiology, cardiology, pathology, orthopaedics, ophthalmology, and genomics), with its VNA and PACS at its core. In the latest KLAS report for customer satisfaction, Sectra's PACS was placed first for the 12th consecutive

More news about: Sectra


Nov 23, 2025, 19:00 ET Innovent Biologics Enters Hang Seng Index and Two Other Major Indices; Global Capital Markets Recognize Leading Innovator's Value

company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that it has been successfully added as a constituent stock of the Hang Seng Index (HSI) following the release

More news about: Innovent Biologics


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.